KLOW Peptide Stack (BPC-157 + TB-500 + GHK-Cu + KPV)

KLOW is a compounding-pharmacy brand stack that extends the popular GLOW formulation (BPC-157 + TB-500 + GHK-Cu) by adding KPV for an explicit anti-inflammatory layer. GLOW in turn is the Wolverine Stack (BPC-157 + TB-500) plus GHK-Cu, so KLOW is best understood as the Wolverine repair backbone with two layers bolted on: copper-peptide collagen remodeling and α-MSH-derived anti-inflammatory signaling. The four peptides are supplied pre-mixed in a single 80 mg vial — typically BPC-157 10 mg, TB-500 10 mg, GHK-Cu 50 mg, and KPV 10 mg — so one injection delivers the full stack. The rationale is four complementary, non-redundant layers of repair biology: BPC-157 drives angiogenesis and growth-factor signaling at injury sites, TB-500 promotes cell migration and actin remodeling for tissue reorganization, GHK-Cu supports collagen synthesis and extracellular matrix rebuilding, and KPV quiets the NF-κB-driven inflammatory tone that otherwise impairs healing and contributes to gut, skin, and autoimmune-adjacent symptoms. KLOW is most often used by people who want the GLOW skin/recovery profile but also have systemic inflammation, gut issues, or inflammatory-skin conditions where the anti-inflammatory coverage matters.

The four peptides act through mechanistically distinct pathways that compound into a broader repair signal than any component alone. BPC-157 upregulates VEGF, EGF, and FGF expression, promoting angiogenesis and granulation tissue formation, and modulates the nitric oxide system with cytoprotective effects across gut, tendon, muscle, and vascular tissue. TB-500 (the synthetic analog of the active region of thymosin beta-4) binds G-actin and regulates actin polymerization, which underpins cell migration, wound closure, and the recruitment of progenitor cells to damaged tissue. GHK-Cu, a copper-binding tripeptide, activates tissue-remodeling gene programs — collagen I and III synthesis, glycosaminoglycan production, and matrix metalloproteinase regulation — and delivers bioavailable copper for lysyl oxidase crosslinking, the step that gives repaired collagen its tensile strength. KPV, the C-terminal tripeptide of α-MSH, inhibits NF-κB signaling, suppresses pro-inflammatory cytokines like TNF-α and IL-6, and has demonstrated mucosal healing and anti-inflammatory effects in colitis and inflammatory skin models. The proposed synergy is a four-phase repair sequence: BPC-157 builds the vascular and growth-factor substrate, TB-500 migrates cells into that substrate, GHK-Cu organizes and crosslinks the new matrix, and KPV keeps the inflammatory tone low enough for the other three to work efficiently. No published trial has tested this combination head-to-head against its components, but the pharmacology is additive rather than overlapping.

Each of the four peptides has its own preclinical evidence base; the KLOW combination has no published human clinical trials. BPC-157 has hundreds of animal studies demonstrating tissue repair across tendon, gut, muscle, and bone, plus a 2026 review covering its role in regeneration and pain management — but human clinical data remains minimal. TB-500 has extensive preclinical work in cardiac, skin, and neural repair; human data is limited to case reports and small open-label series. GHK-Cu has both preclinical and human clinical evidence, with the strongest data for topical skin applications — collagen synthesis, photoaging reversal, and wound healing — including a 2023 study demonstrating GHK-Cu + hyaluronic acid synergy on collagen IV upregulation. KPV has preclinical evidence in colitis, atopic dermatitis, and wound models, but no published human trials for inflammatory bowel disease or any other indication. The KLOW-specific formulation has not been studied. The rationale is a sum-of-components argument — reasonable pharmacologically, but it should not be read as clinically validated at the blend level.

KLOW is supplied as a lyophilized 80 mg vial from compounding pharmacies, reconstituted in bacteriostatic water — typically 2 mL, which yields 40 mg/mL total peptide (BPC-157 5 mg/mL, TB-500 5 mg/mL, GHK-Cu 25 mg/mL, KPV 5 mg/mL). Common subcutaneous dosing in practitioner protocols runs 0.2–0.5 mL (8–20 mg total peptide) per injection, 3–5 times per week for 4–8 weeks, though dose and frequency vary considerably between clinics. Abdominal fat pad is the standard injection site. Some protocols use a higher frequency (daily) for the first 2 weeks then taper to 3x weekly. Because GHK-Cu is the highest-concentration component and delivers copper, cycling is conventional — 4–8 weeks on, 2–4 weeks off — to avoid any theoretical copper accumulation, though the per-dose copper delivery is low. Protocols should be directed by a qualified clinician.